Advagene Biopharma Co., Ltd.


Advagene Biopharma Co., Ltd. is a biopharmaceutical company that aims to develop mucosal immunotherapy, committed to providing human beings around the world the biopharmaceutical development for better epidemic prevention and treatment.

Advagene’s core technology: detoxified LT adjuvant (LTh (αK)) platform, can regulate not only humoral but also mucosal immunity and enhance the production of mucosal immunoglobulin A (IgA), which can fortify the efficacy of vaccines and can change the transmission route; such development has high medical potential. Advagene has applied this into the development of nasal influenza vaccine (AD07030), respiratory allergy treatment (AD17002-AI), COVID-19 immunotherapy (AD17002-SC), nasal COVID-19 vaccine, and other vaccines, among which nasal flu vaccine (AD07030) phase II clinical trial has been completed at the end of the first season in 2019. allergy treatment (AD17002-AI) phase I/II clinical trial is completed and administered in 2020, and COVID-19 immunotherapy (AD17002-SC) phase IIa is initiated in 2021.

Advagene interested in out-licensing or co-development of therapeutics for Covid-19 and respiratory allergy.